Real-world effectiveness and safety of single inhaler triple therapy with beclometasone/ formoterol/ glycopyrronium in moderate to severe asthma: TriMaximize study
To collect prospective data from asthma patients treated with medium- (87/5/9µg) or high-strength (172/5/9µg) extrafine single-inhaler beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G, Trimbow®) in a real-world setting. TriMaximize is a non-interventional, prospective, multice...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
18 February 2026
|
| In: |
Journal of asthma and allergy
Year: 2026, Volume: 19, Pages: 1-21 |
| ISSN: | 1178-6965 |
| DOI: | 10.2147/JAA.S582286 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.2147/JAA.S582286 Verlag, kostenfrei, Volltext: https://www.tandfonline.com/doi/abs/10.2147/JAA.S582286 
|
| Author Notes: | Christian Gessner, Richard EK Russell, Timm Greulich, Marek Lommatzsch, Charlotte Suppli Ulrik, Wolfgang Pohl, Vicente Plaza, Arnaud Bourdin, Maciej Kupczyk, Fulvio Braido, Alessio Piraino, Ulrica Scaffidi-Argentina, Valentina Bogoevska, Frederik Trinkmann |
| Summary: | To collect prospective data from asthma patients treated with medium- (87/5/9µg) or high-strength (172/5/9µg) extrafine single-inhaler beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G, Trimbow®) in a real-world setting. TriMaximize is a non-interventional, prospective, multicenter study conducted in eight European countries (enrollment: 2021-2024). The primary objective was to describe patient characteristics and therapy pathways for adult patients with moderate to severe asthma treated with BDP/FF/G for up to 36 months. Assessments included demographic/clinical characteristics, pulmonary parameters, treatment pathways, asthma control measured by asthma control test (ACT), and health-related quality of life (HrQoL) measured by Mini Asthma Quality of Life Questionnaire (Mini-AQLQ). In total, 1,445 patients (62.8% female; mean age: 57.6 years) were included. Before medium-strength BDP/FF/G initiation, 75.7% of the patients received a fixed ICS/LABA combination. Most patients starting with high-strength BDP/FF/G received fixed ICS/LABA (52.9%) or free ICS/LABA/LAMA (43.2%) combinations as prior therapy. Throughout the study, 87.1% of the patients remained on BDP/FF/G. At month 12, fewer patients (12.4%) used systemic corticosteroids (SCS) compared to baseline (33.2%). Use of rescue medication declined from 6.1 (baseline) to 3.6 puffs/week (month 12). During the first year, 79.5% of the patients experienced neither exacerbations nor used SCS. Three-component clinical remission was achieved in 45.6% (first year) and 59.3% (second/third year) of the patients. Four-component clinical remission was accomplished in 39.5% (first year) and 47.9% (second/third year). Improvements in asthma control (mean ACT change at month 12: 3.9; month 36: 4.8, p<0.0001) and HrQoL (mean Mini-AQLQ change at month 12: 0.8; month 36: 0.9, p<0.0001) exceeded the respective minimal clinically important differences. Forced expiratory volume in 1 second increased by 142 mL after 12 months (p<0.0001). Extrafine, single-inhaler BDP/FF/G therapy was effective and safe in a routine clinical practice setting in a multi-national cohort of patients with moderate to severe asthma. |
|---|---|
| Item Description: | Gesehen am 17.03.2026 |
| Physical Description: | Online Resource |
| ISSN: | 1178-6965 |
| DOI: | 10.2147/JAA.S582286 |